Go to the list of all blogs
Medtronic gets FDA approval for Accurian RF ablation platform - Zacks
Medtronic gets FDA approval for Accurian RF ablation platform - Zacks
Medtronic Plc recently announced the receipt of 510 k clearance from the FDA for its Accurian RF ablation platform. This clearance will help the company with its strategy to strengthen position in the huge chronic pain management market.
Related Ticker: VGHCX
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Notable companies
The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), AstraZeneca PLC (NYSE:AZN), Intuitive Surgical (NASDAQ:ISRG), CVS HEALTH Corp (NYSE:CVS), Edwards Lifesciences Corp (NYSE:EW).
Industry description
The investment seeks long-term capital appreciation.
Under normal circumstances, the fund invests at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in the stocks of companies principally engaged in the development, production, or distribution of products and services related to the health care industry. The adviser may also consider companies engaged in medical, diagnostic, biochemical, and other research and development activities. The fund may invest up to 50% of its assets in foreign stocks. It is non-diversified.
Market Cap
The average market capitalization across the Vanguard Health Care Inv MF is 275.02B. The market cap for tickers in the group ranges from 52.38B to 1.1T. LLY holds the highest valuation in this group at 1.1T. The lowest valued company is EW at 52.38B.
Volume
The average weekly volume growth across all stocks in the Vanguard Health Care Inv MF was -13%. For the same stocks of the MF, the average monthly volume growth was -15% and the average quarterly volume growth was -13%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 35
P/E Growth Rating: 30
Price Growth Rating: 31
SMR Rating: 55
Profit Risk Rating: 61
Seasonality Score: -36 (-100 ... +100)
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information
General Information
Category Health
Profile
Details
Category
Health
Address
Vanguard Specialized FundsPo Box 2600 V26Valley Forge
Phone
6106696295
Web
www.vanguard.com
Interact to see
Advertisement
Advertisement